EMA Application withdrawn: Solithromycin Triskel EU Services (solithromycin) — Triskel EU Services Ltd

View source ↗

Summary

The EMA reports withdrawal of the Solithromycin application by Triskel EU Services Ltd for uses including tularemia, pneumonia, and anthrax.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthrax
• Pneumonia
• Tularemia

Drugs mentioned

• Solithromycin (solithromycin)

Snippet

Status: Application withdrawn. Therapeutic area: Tularemia;Pneumonia;Anthrax. MAH: Triskel EU Services Ltd. Decision date: 21/04/2017